Treatment Paradigms for Advanced Non-Small Cell Lung Cancer at Academic Medical Centers: Involvement in Clinical Trial Endpoint Design

Overview

Journal Oncologist

Publisher Oxford University Press

Specialty Oncology

Date 2017 Apr 15

PMID 28408617

Citations 9

Authors

Charu Aggarwal

Hossein Borghaei

Affiliations

Soon will be listed here.

Abstract

Implications For Practice: While improving survival remains the ultimate goal of oncology clinical trials, overall survival may not always be the most feasible or appropriate endpoint to assess patient response. Recently, several investigational agents, both targeted agents and immunotherapies, have gained U.S. Food and Drug Administration approval in non-small cell lung cancer based on alternate endpoints such as progression-free survival or response rate. An understanding of the assessment of response and trial endpoint choice is important for future oncology clinical trial design.

Citing Articles

[Research Progress of DNA Methylation in Cisplatin Resistance in Lung Cancer].

Sun J, Chen J Zhongguo Fei Ai Za Zhi. 2023; 26(1):52-58.

PMID: 36792081 PMC: 9987084. DOI: 10.3779/j.issn.1009-3419.2023.101.03.

OSPred Tool: A Digital Health Aid for Rapid Predictive Analysis of Correlations Between Early End Points and Overall Survival in Non-Small-Cell Lung Cancer Clinical Trials.

Shameer K, Zhang Y, Prokop A, Nampally S, N I, Weatherall J JCO Clin Cancer Inform. 2022; 6:e2100173.

PMID: 35467964 PMC: 9067362. DOI: 10.1200/CCI.21.00173.

Use of diffusion-weighted magnetic resonance imaging (DW-MRI) to predict early response to anti-tumor therapy in advanced non-small cell lung cancer (NSCLC): a comparison of intravoxel incoherent motion-derived parameters and apparent diffusion....

Yuan Z, Niu X, Liu X, Fu H, Xue T, Koo C Transl Lung Cancer Res. 2021; 10(8):3671-3681.

PMID: 34584865 PMC: 8435389. DOI: 10.21037/tlcr-21-610.

Guaiazulene Triggers ROS-Induced Apoptosis and Protective Autophagy in Non-small Cell Lung Cancer.

Ye Q, Zhou L, Jin P, Li L, Zheng S, Huang Z Front Pharmacol. 2021; 12:621181.

PMID: 33935713 PMC: 8082441. DOI: 10.3389/fphar.2021.621181.

Upregulation of Serum miR-629 Predicts Poor Prognosis for Non-Small-Cell Lung Cancer.

Liu F, Li T, Hu P, Dai L Dis Markers. 2021; 2021:8819934.

PMID: 33763157 PMC: 7946467. DOI: 10.1155/2021/8819934.

References

Borghaei H, Paz-Ares L, Horn L, Spigel D, Steins M, Ready N . Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. N Engl J Med. 2015; 373(17):1627-39. PMC: 5705936. DOI: 10.1056/NEJMoa1507643. View

Camidge D, Bang Y, Kwak E, Iafrate A, Varella-Garcia M, Fox S . Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. Lancet Oncol. 2012; 13(10):1011-9. PMC: 3936578. DOI: 10.1016/S1470-2045(12)70344-3. View

Sequist L, Yang J, Yamamoto N, OByrne K, Hirsh V, Mok T . Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol. 2013; 31(27):3327-34. DOI: 10.1200/JCO.2012.44.2806. View

Ioannou N, Seddon A, Dalgleish A, Mackintosh D, Modjtahedi H . Treatment with a combination of the ErbB (HER) family blocker afatinib and the IGF-IR inhibitor, NVP-AEW541 induces synergistic growth inhibition of human pancreatic cancer cells. BMC Cancer. 2013; 13:41. PMC: 3598209. DOI: 10.1186/1471-2407-13-41. View

Solca F, Dahl G, Zoephel A, Bader G, Sanderson M, Klein C . Target binding properties and cellular activity of afatinib (BIBW 2992), an irreversible ErbB family blocker. J Pharmacol Exp Ther. 2012; 343(2):342-50. DOI: 10.1124/jpet.112.197756. View

Shaw A, Gandhi L, Gadgeel S, Riely G, Cetnar J, West H . Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial. Lancet Oncol. 2015; 17(2):234-242. PMC: 4752892. DOI: 10.1016/S1470-2045(15)00488-X. View

Garassino M, Martelli O, Broggini M, Farina G, Veronese S, Rulli E . Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial. Lancet Oncol. 2013; 14(10):981-8. DOI: 10.1016/S1470-2045(13)70310-3. View

Wozniak A, Crowley J, Balcerzak S, Weiss G, Spiridonidis C, Baker L . Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small-cell lung cancer: a Southwest Oncology Group study. J Clin Oncol. 1998; 16(7):2459-65. DOI: 10.1200/JCO.1998.16.7.2459. View

Reck M, Kaiser R, Mellemgaard A, Douillard J, Orlov S, Krzakowski M . Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial. Lancet Oncol. 2014; 15(2):143-55. DOI: 10.1016/S1470-2045(13)70586-2. View

10.

Johnson J, Williams G, Pazdur R . End points and United States Food and Drug Administration approval of oncology drugs. J Clin Oncol. 2003; 21(7):1404-11. DOI: 10.1200/JCO.2003.08.072. View

11.

Garon E, Ciuleanu T, Arrieta O, Prabhash K, Syrigos K, Goksel T . Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial. Lancet. 2014; 384(9944):665-73. DOI: 10.1016/S0140-6736(14)60845-X. View

12.

Bonomi P, Kim K, Fairclough D, Cella D, Kugler J, Rowinsky E . Comparison of survival and quality of life in advanced non-small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: results of an Eastern Cooperative Oncology Group trial. J Clin Oncol. 2000; 18(3):623-31. DOI: 10.1200/JCO.2000.18.3.623. View

13.

Korn E, Freidlin B, Abrams J . Overall survival as the outcome for randomized clinical trials with effective subsequent therapies. J Clin Oncol. 2011; 29(17):2439-42. PMC: 3107757. DOI: 10.1200/JCO.2011.34.6056. View

14.

Ou S, Ahn J, De Petris L, Govindan R, Yang J, Hughes B . Alectinib in Crizotinib-Refractory ALK-Rearranged Non-Small-Cell Lung Cancer: A Phase II Global Study. J Clin Oncol. 2015; 34(7):661-8. DOI: 10.1200/jco.2015.63.9443. View

15.

Blumenthal G, Karuri S, Zhang H, Zhang L, Khozin S, Kazandjian D . Overall response rate, progression-free survival, and overall survival with targeted and standard therapies in advanced non-small-cell lung cancer: US Food and Drug Administration trial-level and patient-level analyses. J Clin Oncol. 2015; 33(9):1008-14. PMC: 4356710. DOI: 10.1200/JCO.2014.59.0489. View

16.

Wolchok J, Hoos A, ODay S, Weber J, Hamid O, Lebbe C . Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res. 2009; 15(23):7412-20. DOI: 10.1158/1078-0432.CCR-09-1624. View

17.

Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E . Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2012; 13(3):239-46. DOI: 10.1016/S1470-2045(11)70393-X. View

18.

Garon E . Issues surrounding clinical trial endpoints in solid malignancies with a focus on metastatic non-small cell lung cancer. Lung Cancer. 2012; 77(3):475-81. PMC: 3737740. DOI: 10.1016/j.lungcan.2012.06.007. View

19.

Le Chevalier T, Brisgand D, Douillard J, Pujol J, Alberola V, Monnier A . Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: results of a European multicenter trial including 612 patients. J Clin Oncol. 1994; 12(2):360-7. DOI: 10.1200/JCO.1994.12.2.360. View

20.

Miller V, Hirsh V, Cadranel J, Chen Y, Park K, Kim S . Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial. Lancet Oncol. 2012; 13(5):528-38. DOI: 10.1016/S1470-2045(12)70087-6. View